EARNINGS PER SHARE

9 Months Ended

Sep. 30, 2023

Basic earnings per share is computed by dividing net income by the weighted-average common shares outstanding during the period. Diluted earnings per share is computed based on the weighted-average common shares outstanding plus the effect of dilutive potential common shares outstanding during the period calculated using the treasury stock method. Dilutive potential common shares include employee equity share options, nonvested shares, and similar equity instruments granted by the Company. Potential common share equivalents have been excluded where their inclusion would be anti-dilutive.

The table below presents the computation of basic and diluted earnings per share (in millions, except for per share information):


	Three Months Ended September 30,				Nine Months Ended September 30,
	2023		2022		2023		2022
Basic:
Net income attributable to Edwards Lifesciences Corporation	$	384.9	$	343.5	$	1,032.5	$	1,123.5
Weighted-average shares outstanding	607.0		619.8		607.2		621.0
Basic earnings per share	$	0.63	$	0.55	$	1.70	$	1.81
Diluted:
Net income attributable to Edwards Lifesciences Corporation	$	384.9	$	343.5	$	1,032.5	$	1,123.5
Weighted-average shares outstanding	607.0		619.8		607.2		621.0
Dilutive effect of stock plans	2.5		4.7		3.0		5.9
Dilutive weighted-average shares outstanding	609.5		624.5		610.2		626.9
Diluted earnings per share	$	0.63	$	0.55	$	1.69	$	1.79

Stock options, restricted stock units, and market-based restricted stock units to purchase an aggregate of 6.5 million and 4.0 million common shares for the three months ended September 30, 2023 and 2022, respectively, and 6.1 million and 3.1 million shares for the nine months ended September 30, 2023 and 2022, respectively, were outstanding, but were not included in the computation of diluted earnings per share for such periods because the effect would have been anti-dilutive.